Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $134.2 million.

  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) rose 15.41% to $134.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.2 million, marking a year-over-year increase of 15.41%. This contributed to the annual value of $114.5 million for FY2024, which is 19.02% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Shares Outstanding (Diluted Average) of $134.2 million as of Q3 2025, which was up 0.36% from $133.7 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $134.2 million during Q3 2025, and registered a low of $90.5 million during Q1 2022.
  • In the last 3 years, Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $109.5 million in 2024 and averaged $111.3 million.
  • Data for Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY soared of 33.18% (in 2025) over the last 5 years.
  • Over the past 4 years, Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $93.4 million in 2022, then rose by 2.97% to $96.2 million in 2023, then rose by 19.02% to $114.5 million in 2024, then rose by 15.41% to $134.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $134.2 million for Q3 2025, versus $133.7 million for Q2 2025 and $133.0 million for Q1 2025.